Rapid test can assist emergency care clinicians in differentiation of bacterial vs. viral infections to reduce inappropriate prescribing of antibiotics for respiratory infections.
Lumos Diagnostics (ASX: LDX) today announced has received clearance from the US Food and Drug Administration to market its FebriDx® rapid, point-of-care test in the United States.
The clearance allows FebriDx to be marketed in the US for use by healthcare professionals as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology in patients presenting in urgent care or emergency care settings. FebriDx is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection.
Following a presubmission meeting in January 2023, Lumos submitted a new 510(k) application for FebriDx to the FDA earlier this year. The FDA has completed its review of this new application and determined that FebriDx has demonstrated substantial equivalence to the predicate device cited in this application, and has consequently cleared it for marketing in the US.
FebriDx is already registered in the UK, Europe, Canada, UAE, Brazil, Turkey, Pakistan, Singapore, Malaysia and Australia.
The inappropriate and unnecessary prescribing of antibiotics is recognised as a significant contributing factor to the growing global emergence of antimicrobial resistant (AMR) strains of bacterial pathogens. In 2021, US healthcare professionals in outpatient settings issued 211 million prescriptions for antibiotics—equivalent to 636 prescriptions per 1,000 persons1. Despite acute respiratory infections being predominantly viral in origin, they are the most common diagnosis for which antibiotics are prescribed and up to 40% of these prescriptions are considered unnecessary2. As a consequence, one of the core elements of the Centers for Disease Control and Prevention Outpatient Antibiotic Stewardship program is to improve antibiotic prescribing by clinicians and their use in patients so that antibiotics are only prescribed and used when needed.
“We are delighted to finally secure clearance to market our FebriDx rapid, point-of-care test in the US as we continue to believe it has an important role to play in antibiotic stewardship,” said Doug Ward, CEO of Lumos Diagnostics.
2. Antibiotics 2022, 11, 1058. https://doi.org/10.3390/antibiotics11081058